Sou Hu Cai Jing·2026-01-29 10:23Core Viewpoint - The company, Tigermed, forecasts a revenue range of RMB 6.66 billion to RMB 7.68 billion for the year 2025, indicating a return to growth after a previous decline [1][3]. Financial Performance - The non-recurring gains attributable to shareholders are expected to be between RMB 500 million and RMB 740 million, a significant increase from the previous year's loss of RMB 449.75 million, resulting in a net increase of RMB 949.75 million to RMB 1.18975 billion [2]. - The net profit attributable to shareholders, excluding non-recurring gains, is projected to be between RMB 330 million and RMB 490 million, a decrease of 43% to 61% compared to the previous year's profit of RMB 854.90 million [5]. - The net cash flow from operating activities is estimated to be between RMB 1.1 billion and RMB 1.3 billion, reflecting a slight increase from RMB 1.097 billion in the previous year [4]. Market Position and Industry Trends - The company maintains its leading position in China's clinical research outsourcing (CRO) industry, with a market share that remains the highest according to Frost & Sullivan [3]. - The demand for clinical research outsourcing services continues to recover, driven by the resurgence of the innovative drug industry in China and the integration of the clinical research supply chain into the global landscape [3]. - The company has seen a good growth in new orders, with net new orders expected to be between RMB 9.5 billion and RMB 10.5 billion, compared to RMB 8.42 billion in the previous year [3]. Operational Insights - The company has implemented risk screening measures to identify potential risks and adjust fair value accordingly, which has contributed to the increase in investment income and fair value changes from non-current financial assets [2]. - The average price of new orders has stabilized after a decline due to competitive pressures in the clinical research outsourcing industry [5].